Company: CSTL
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001447362-25-000097
Chunk: 146

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-08-04
Form: 10-Q
Item: Item 8
Chunk 146
---
 the amount of stock-based compensation expense (non-cash) reflected in the line items above (in thousands):

Six Months EndedJune 30,20252024Change(unaudited)Cost of sales (exclusive of amortization of acquired intangible assets)$2,878 $2,715 $163 Research and development3,857 5,266 (1,409)Selling, general and administrative15,652 17,873 (2,221)Total stock-based compensation expense$22,387 $25,854 $(3,467)

37

The following table provides a disaggregation of net revenues by type (in thousands):

Six Months EndedJune 30,20252024Change(unaudited)Dermatologic(1)$119,259 $128,163 $(8,904)Non-Dermatologic(2)54,917 31,813 23,104 Total net revenues$174,176 $159,976 $14,200 

(1)Consists of DecisionDx-Melanoma, DecisionDx-SCC and our Diagnostic GEP offering. 

(2)Consists of TissueCypher, DecisionDx-UM and IDgenetix.

The following table presents the calculation of gross margin (in thousands, except percentages):

 Six Months EndedJune 30, 20252024Change(unaudited)Net revenues$174,176 $159,976 $14,200 Less: Cost of sales (exclusive of amortization of acquired intangible assets)34,009 28,413 5,596 Less: Amortization of acquired intangible assets30,286 4,494 25,792 Gross margin$109,881 $127,069 $(17,188)Gross margin percentage63.1 %79.4 %(16.3)%

Net Revenues

Net revenues for the six months ended June 30, 2025 increased by $14.2 million, or 8.9%, to $174.2 million compared to the six months ended June 30, 2024, due to a $23.1 million increase in revenue from our non-dermatologic tests and a $8.9 million decrease in revenue from our dermatologic tests.

The $23.1 million increase in revenue from our non-dermatologic tests was largely attributable to a 102.2% increase